These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 12165228)
41. Case definition of psoriatic arthritis. Marzo-Ortega H; McGonagle D; Veale D; Emery P Lancet; 2000 Dec; 356(9247):2095; author reply 2096. PubMed ID: 11145513 [No Abstract] [Full Text] [Related]
42. Case definition of psoriatic arthritis. Spadaro A; Riccieri V; Taccari E Lancet; 2000 Dec; 356(9247):2095-6; author reply 2096. PubMed ID: 11145511 [No Abstract] [Full Text] [Related]
43. Etanercept for the treatment of psoriasis. Bissonnette R Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060 [TBL] [Abstract][Full Text] [Related]
44. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N; Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305 [No Abstract] [Full Text] [Related]
45. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. de Vlam K; Lories RJ Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275 [TBL] [Abstract][Full Text] [Related]
46. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Chong BF; Wong HK Clin Exp Dermatol; 2009 Jul; 34(5):e11-3. PubMed ID: 19040508 [TBL] [Abstract][Full Text] [Related]
47. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060 [TBL] [Abstract][Full Text] [Related]
48. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society]. Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517 [No Abstract] [Full Text] [Related]
49. Do TNF-blockers reduce or induce uveitis? Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974 [No Abstract] [Full Text] [Related]
50. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. Kimball AB; Jackson JM; Sobell JM; Boh EE; Grekin S; Pharmd EB; Woolley JM; Xia HA; Chiou CF; Stevens SR J Drugs Dermatol; 2007 Mar; 6(3):299-306. PubMed ID: 17373192 [TBL] [Abstract][Full Text] [Related]
58. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. Yamauchi PS; Lowe NJ; Gindi V J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S121-2. PubMed ID: 16488323 [No Abstract] [Full Text] [Related]
59. Effective control of psoriasis by etanercept in a patient with HCV-related diseases. Piccolo D; Di Cesare A; Fargnoli MC; Paoloni M; Vecchiotti S; Peris K Eur J Dermatol; 2008; 18(4):459-60. PubMed ID: 18573723 [No Abstract] [Full Text] [Related]
60. Safety and efficacy study on etanercept in patients with plaque psoriasis. Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]